Stoke Therapeutics (NASDAQ:STOK) Stock Crosses Above Fifty Day Moving Average – Should You Sell?

Stoke Therapeutics, Inc. (NASDAQ:STOK) passed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $27.09 and traded as high as $27.75. Stoke Therapeutics shares last traded at $27.45, with a volume of 1,209,951 shares.

Key Stories Impacting Stoke Therapeutics

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: HC Wainwright modestly improved its FY2028 EPS estimate to a loss of $1.74 per share from a loss of $1.78, indicating a slightly smaller projected loss in that year. HC Wainwright Cuts Earnings Estimates for Stoke Therapeutics
• Neutral Sentiment: The company plans to present at investor conferences in November; the announcement does not provide new clinical or financial results. Stoke Therapeutics to Present at Upcoming Investor Conferences in November
• Negative Sentiment: HC Wainwright cut its FY2026 EPS estimate to a loss of $3.93 from $3.35 and its FY2027 estimate to a loss of $3.98 from $2.55. It also lowered its Q4 2026 estimate to a loss of $1.11 from $0.81. The larger projected losses are the clearest near-term negative for STOK. HC Wainwright Cuts Earnings Estimates for Stoke Therapeutics

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Stoke Therapeutics in a research report on Friday, August 7th. Wedbush lifted their target price on Stoke Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. Guggenheim reiterated a “buy” rating and set a $60.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. The Goldman Sachs Group reissued a “buy” rating and issued a $43.00 price target on shares of Stoke Therapeutics in a report on Friday, October 30th. Finally, Canaccord Genuity Group cut their price objective on shares of Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating for the company in a research report on Tuesday, August 4th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $44.17.

Stoke Therapeutics Stock Performance

The stock’s 50 day moving average price is $27.09 and its 200-day moving average price is $30.84. The company has a market cap of $1.77 billion, a PE ratio of -7.28 and a beta of 1.36.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Thursday, October 29th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.15). Stoke Therapeutics had a negative net margin of 862.07% and a negative return on equity of 66.76%. The company had revenue of $11.26 million during the quarter, compared to the consensus estimate of $8.21 million. On average, analysts anticipate that Stoke Therapeutics, Inc. will post -3.78 EPS for the current year.

Insider Activity at Stoke Therapeutics

In related news, Director Edward Kaye sold 12,567 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total transaction of $402,521.01. Following the transaction, the director owned 124,557 shares in the company, valued at $3,989,560.71. The trade was a 9.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Barry Ticho sold 5,545 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $30.67, for a total value of $170,065.15. Following the transaction, the insider owned 20,110 shares of the company’s stock, valued at approximately $616,773.70. This represents a 21.61% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 27,418 shares of company stock worth $860,914 in the last 90 days. Company insiders own 9.60% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Versant Capital Management Inc lifted its stake in shares of Stoke Therapeutics by 22.6% in the second quarter. Versant Capital Management Inc now owns 1,951 shares of the company’s stock worth $64,000 after buying an additional 359 shares in the last quarter. First Trust Advisors LP lifted its holdings in Stoke Therapeutics by 0.5% in the first quarter. First Trust Advisors LP now owns 163,459 shares of the company’s stock valued at $5,322,000 after acquiring an additional 780 shares during the period. Quantbot Technologies LP purchased a new position in shares of Stoke Therapeutics in the second quarter worth approximately $34,000. KBC Group NV purchased a new position in shares of Stoke Therapeutics during the 1st quarter worth $36,000. Finally, EverSource Wealth Advisors LLC grew its holdings in Stoke Therapeutics by 195.3% during the first quarter. EverSource Wealth Advisors LLC now owns 1,837 shares of the company’s stock valued at $60,000 after purchasing an additional 1,215 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases caused by insufficient protein production. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to design antisense oligonucleotides that can increase the expression of specific genes and potentially address the underlying causes of genetic disorders.

Stoke’s leading product candidate is STK-001, an investigational antisense oligonucleotide being developed for the treatment of Dravet syndrome, a severe genetic epilepsy most commonly associated with mutations in the SCN1A gene.